Physician profile
Bishop A Mitchell
NPI 1699358614
$829.96
in general payments reported to CMS, 2019-2025
18 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $157 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $173.42 | 2025 | Veozah |
| Pfizer INC. | $151.18 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.05 | 2024-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $54.40 | 2025 | |
| Janssen Pharmaceuticals, INC | $50.25 | 2024-2025 | Spravato |
| Dexcom, INC. | $48.04 | 2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $47.55 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $39.05 | 2024-2025 | Gemtesa |
| Organon LLC | $32.18 | 2024-2025 | Nexplanon |
| Lilly USA, LLC | $30.46 | 2024-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.15 | 2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $20.36 | 2024 | |
| Novo Nordisk INC | $18.47 | 2025 | Ozempic, Rybelsus |
| Ascensia Diabetes Care US INC. | $18.24 | 2025 | |
| Abbott Laboratories | $17.08 | 2025 | Freestyle Libre 3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $15.31 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $14.44 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $14.33 | 2025 | Arexvy, Bexsero, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bishop Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.